Thrivent Financial for Lutherans Buys 164,111 Shares of Haemonetics Co. (NYSE:HAE)

Thrivent Financial for Lutherans lifted its stake in Haemonetics Co. (NYSE:HAE - Free Report) by 14.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,264,294 shares of the medical instruments supplier's stock after purchasing an additional 164,111 shares during the quarter. Thrivent Financial for Lutherans owned 2.52% of Haemonetics worth $98,716,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently modified their holdings of the company. Parkside Financial Bank & Trust raised its position in shares of Haemonetics by 25.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after purchasing an additional 240 shares during the last quarter. AlphaQuest LLC raised its position in Haemonetics by 36,520.0% in the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock worth $143,000 after buying an additional 1,826 shares during the last quarter. KBC Group NV raised its position in Haemonetics by 54.6% in the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock worth $157,000 after buying an additional 712 shares during the last quarter. iSAM Funds UK Ltd purchased a new position in Haemonetics in the 3rd quarter worth about $204,000. Finally, HighTower Advisors LLC raised its position in Haemonetics by 7.8% in the 4th quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock worth $262,000 after buying an additional 244 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Remove Ads

Analysts Set New Price Targets

HAE has been the subject of a number of recent analyst reports. Bank of America lowered Haemonetics from a "neutral" rating to an "underperform" rating and decreased their target price for the stock from $95.00 to $68.00 in a research report on Friday, February 7th. JMP Securities decreased their target price on Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a research report on Friday, February 7th. JPMorgan Chase & Co. initiated coverage on Haemonetics in a research report on Friday, December 6th. They issued an "overweight" rating and a $116.00 target price for the company. Needham & Company LLC decreased their target price on Haemonetics from $108.00 to $104.00 and set a "buy" rating for the company in a research report on Tuesday, March 18th. Finally, Barrington Research decreased their target price on Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $101.22.

Haemonetics Stock Performance

Shares of Haemonetics stock traded down $0.16 during trading hours on Friday, reaching $64.08. 887,916 shares of the stock traded hands, compared to its average volume of 651,087. The company has a 50 day moving average price of $67.29 and a 200 day moving average price of $75.03. The firm has a market capitalization of $3.22 billion, a price-to-earnings ratio of 25.23, a P/E/G ratio of 1.11 and a beta of 0.43. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a one year low of $58.80 and a one year high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, equities research analysts expect that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.